Clinical Trials

Inclusion Criteria:

• Age ≥ 21 to ≤ 85 years at signing of informed consent.
• Diagnosis of heart failure, defined as requiring pharmacologic treatment for heart failure, with NYHA class II to class III at most recent screening assessment.
• Screening within 30 days after hospitalization for heart failure – either as a primary or secondary diagnosis.
• istory of (within the past 6 H) or current use of diuretics.
• HF patient who is willing to comply with study restrictions including Everion® device management (wearing and charging the device), Apple watch Series 4 and above device management (wearing and charging the device) and BiovitalsHF Patient App Management (pairing Everion® device and Apple watch Series 4 and above and BiovitalsHF Patient App, and carrying the smartphone for answering questionnaires and data reporting).

Exclusion Criteria:

• Acute coronary syndrome (ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, unstable angina) stroke, or transient ischemic attack, major cardiac surgery, percutaneous coronary intervention, or valvuloplasty within the 30 days prior to screening.
• Uncontrolled hypertension defined as sitting systolic blood pressure (SBP) ≥ 180 mm Hg or diastolic BP (DBP) ≥ 110 mm Hg.
• Untreated severe ventricular arrhythmia (e.g., ventricular tachycardia or ventricular fibrillation).
• Symptomatic bradycardia or second or third-degree heart block without a pacemaker.
• Malignancy except non-melanoma skin cancers, cervical or breast ductal carcinoma in situ within the last 5 years.
• Hospitalization with any pathology that may meaningfully interfere with functional tolerance, cardiopulmonary capacity or mobility within the 30 days prior to screening.
• Estimated glomerular filtration rate (eGFR) < 20 mL/min/1.73 m^2 or receiving dialysis at screening.
• Routinely scheduled outpatient intravenous infusions for heart failure (e.g., inotropes, vasodilators [e.g., nesiritide], diuretics) or routinely scheduled ultrafiltration.
• Currently receiving treatment or procedure in another investigational device or drug study.
• Likely to receive during the duration of the study, in the opinion of the investigator, planned revascularization, implantation of ICD or CRT, ventricular assist device, continuous or intermittent inotropic therapy, hospice care, or cardiac transplant.
• Implantable cardioverter defibrillator or initiation of cardiac resynchronization therapy (CRT) (with/without implantable cardioverter defibrillator) within 30 days prior to enrollment.
• Recipient of any major organ transplant (e.g., lung, liver, heart, bone marrow, kidney).
• Less than 4 months prior Interventional Clinical Study participation.
• Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (e.g., Clinical Outcome Assessments) to the best of the subject and investigator’s knowledge.
• History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
• Any individuals that are lacking the ability to consent.

Eligibility last updated 8/23/21. Questions regarding updates should be directed to the study team contact.